Results of Treatment and Prognostic Factors of Lymphoblastic Leukemia: An Analysis in 33 Patients.
- Author:
You Sook CHO
1
;
Kyoo Hyung LEE
;
Je Hwan LEE
;
Sung Bae KIM
;
Sang We KIM
;
Cheol Won SUH
;
Jung Shin LEE
;
Woo Kun KIM
;
Sang Hee KIM
;
Hyun Sook CHI
;
Chan Jung PARK
Author Information
1. Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Adult ALL;
VPDL chemotherapy;
Immunologic markers
- MeSH:
Adult;
B-Lymphocytes;
Biomarkers;
Drug Therapy;
Humans;
Induction Chemotherapy;
Precursor Cell Lymphoblastic Leukemia-Lymphoma*;
Serum Albumin
- From:Korean Journal of Medicine
1997;52(3):315-325
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: Rate of complete remission and long-term survival in adult acute lymphoblastic leukemia group has not been as satisfactory as that in childhood ALL. Recently introduction of induction chemotherapy of more intensive combination and various trials of postremission therapy are making improved results better looked forward to. And subtypes of ALL according to the degree of differentiation into T and B cells are identified by using immunologic markers hopefully to work out proper treatment for each subtype. METHODS: We analited results of treatment and differences of complete remission rate, remission duration and overall survival as to various immunologic markers and clinicopathologic characteristics in 33adult ALL patients. RESULTS: Eighty five percents of the 27cases that had VPDL chemotherapy achieved complete remission and both overall median survival and mediom duration of remission were 52weeks. No definite prognostic factors were detected influencing complete remission rate, remission duration and overall survival except that patients with serum albumin level higher than 4.0mg/dL showed highter complete remission rate. Although mature B-ALL showed the shortest overall median survival, degree of differenciation of B-cell and other immunologic markers did not influence on complete remission rate, remission duration or overall survival. CONCLUSION: Further studies are needed to delire the prognostic factors in adult ALL.
